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Strengths and limitations of this study
 ► For the first time, the amount of patient- by- treatment 
interaction (treatment heterogeneity), a necessary 
prerequisite for personalised medicine, is estimat-
ed for the pharmacological treatment of depression 
with antidepressants.
 ► The database is from a systematic review of pub-
lished and unpublished studies and is one of the 
largest so far, resulting in precise estimations of the 
main outcomes.
 ► The study results are important to inform further 
attempts in personalised (precision) medicine in 
psychiatry.
 ► As with all clinical trials, it remains an open question 
if our results can be replicated in real- world settings, 
for example among psychiatric inpatients with very 
severe depression.
AbStrACt
Objectives To investigate if the treatment effect of 
antidepressants in patients with depression substantially 
varies in each patient (patient- by- treatment interaction 
or treatment heterogeneity), a necessary but largely 
unexplored prerequisite of personalised antidepressant 
treatment.
Design Meta- analytic variance comparison of treatment 
outcome between drug arms and placebo arms of clinical 
trials, based on the assumption that patient- by- treatment 
interaction should lead to larger variances in drug arms 
than placebo arms. To put the results into context, we 
run simple simulations, assuming different definitions 
and rates of those who respond especially well to 
antidepressants.
Data sources 163 randomised, placebo- controlled trials 
(51 396 patients) with complete results for pre–post 
differences, selected from a recently published systematic 
review.
Analysis Variance ratios (VRs) and coefficients of variance 
ratios (CVRs) of individual trials were meta- analytically 
combined. The analysis was repeated for classes of 
antidepressants and specific antidepressants.
results VRs (VR=1.01, CI 0.99 to 1.02) and CVRs 
(CVR=0.82, CI 0.80 to 0.84) of the antidepressant- 
treatment arms were comparable or smaller than in 
placebo arms. Similar results were observed for classes 
of antidepressants and for specific antidepressants. Our 
simulation analysis confirmed that equal VRs can only 
be obtained if they are not more than a few patients who 
respond slightly above average.
Conclusions The lack of increased treatment- outcome 
variance in the antidepressants versus placebo groups 
in randomised controlled trials indicates that no or only 
very small subgroups of patients respond particularly 
well to antidepressants. Thus, the scope for personalised 
treatment with antidepressants seems to be limited.
IntrODuCtIOn
Personalised or precision medicine, that 
is, applying medical interventions only to 
those patients known to benefit especially 
well to the intervention (henceforth termed 
‘benefiters’), is important to increase 
benefits from treatment and to decrease 
harms. For example, if a drug with severe 
side effects is very effective in some patients 
with a specific genotype, it is crucial to know 
about these benefiters, because for all other 
patients, the risk–benefit ratio would be 
unfavourable. Similarly, if a drug is found to 
have only modest efficacy across all patients 
but notable side effects, then it would be 
important to know if there are patients (eg, 
those defined via a specific biomarker) who 
are benefiters. The latter example corre-
sponds with the pharmacological treat-
ment of major depression, because the 
average efficacy of antidepressants (ADs) is 
modest, corresponding to, on average, only 
about 2 points difference on the Hamilton 
Depression Rating Scale (HDRS) between 
AD groups and placebo in short- term 
randomised controlled trials (RCTs).1–5 Put 
differently, according to our most recent 
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estimate, there is about 88% overlap in distribution of 
depression scores between ADs and placebo at the end 
of acute treatment.2
Despite substantial research efforts, no predictors of 
treatment success with ADs were found that were robust 
and reliable enough for use in clinical practice.6–9 Thus, 
much of the variance of the treatment outcome remains 
unexplained so far. Sources of outcome variation include 
variation between treatment arms (indicating that group 
means differ due to efficacy of treatments, eg, ADs vs 
placebo), variation between patients (indicating that the 
outcome differs from patient to patient, independent of 
the treatment received), variation within patients (indi-
cating that the outcome for the same patient differs 
over time due to random symptom fluctuations) and 
patient- by- treatment interactions (indicating that treat-
ment effects vary from patient to patient).10 The quest 
for precision psychiatry, in this case—personalised AD 
treatment, assumes that specific patients benefit more 
from ADs than others, that is, assumes that there is a 
patient- by- treatment interaction. Ideally, this can also be 
explained by a plausible causal mechanism, for example, 
inter- individual differences in monoamine function. 
Investing research efforts in personalised medicine only 
makes sense if there truly is a patient- by- drug interaction 
that explains some variance in the treatment outcome. 
Although the field is mostly enthusiastic about person-
alised medicine or precision psychiatry,11 experts from 
various fields now start to dampen expectations and 
caution that personalised/precision medicine may fall 
short of expectations.12–14
Thus, we must remain mindful that there might be 
no notable subgroup of true AD benefiters and that the 
modest average treatment effect is the best we can hope 
for.15 We further need to acknowledge that RCTs are 
inherently limited to demonstrating patient- by- treatment 
interactions.10 To identify patient- by- treatment inter-
actions, repeated period cross- over trials are necessary, 
but these are hardly feasible with common ADs due to 
delayed onset of therapeutic effect and relatively high 
rates of spontaneous remission. The most common trial 
design is the simple parallel- group trial, where patients 
are randomised to either ADs or placebo. However, 
these trials can only identify mean differences between 
treatment arms (ie, efficacy), whereas variation between 
patients, within patients, as well as patient- by- treatment 
interactions are part of the error term. Nevertheless, 
if patient- by- treatment interaction effects are present, 
then the variance in the treatment outcome should be 
increased in the drug group relative to the placebo group, 
because no comparable drug- by- patient interaction is 
present in the placebo group.10 16 17 Thus, results from 
RCT can inform indirectly if there might be subgroups 
of benefiters.
The goal of this meta- analysis was to examine whether 
the outcome variances between ADs and placebo differ, 
in order to gauge the potential of personalised/precision 
psychiatry for treatment with ADs.
MethODS
Data
Our analysis was based on short- term RCTs of ADs for 
patients with unipolar major depression, reported in 
the most recent systematic review.18 The authors of 
this comprehensive study made the data available in a 
public repository (https:// data. mendeley. com/ data-
sets/ 83rthbp8ys/ 2). This included 522 trials (with 21 
different ADs), of which 254 trials were suitable for 
further analysis, that is, contained information about the 
outcome and also included a placebo arm. Where trials 
had multiple treatment arms with different dosages of 
ADs, these arms were aggregated. Where trials compared 
different ADs, the data of these arms were aggregated to 
only have one value for the drugs in these trials, similar 
as in a previous publication.16 Additionally, we recorded 
different ADs by their class [serotonin- norepinephrine 
reuptake inhibitor (SNRI), selective serotonin reuptake 
inhibitor (SSRI), atypical ADs, and tricyclic ADs]. For 169 
(67%) of studies, the pre- post mean reduction of depres-
sion scores (M) and the related SDs were available, and 
only the analysis for these studies is reported here. Anal-
ysis for the 85 studies (33%) where only the mean value 
and SD of the post- treatment depression scores were 
available are reported in the (online supplementary file 
1,https:// osf. io/ 98kex/ files/). Several additional vari-
ables were created for sensitivity analysis (see statistical 
analysis).
Patient and public involvement statement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
Statistical analysis
Meta-analysis
We calculated the variance ratio (VR) for each RCT and 
aggregated them by means of a random effect meta- 
analysis according to the procedure suggested by Winkel-
beiner et al16; see https:// osf. io/ qarvs/ files/, using the 
metafor package in R. Because the pre–post differences 
were significantly associated with their SD, we repeated 
the analysis using the coefficient of the variance ratio 
(CVR). This removes the effect of expected changes 
in the SD due to changes in the mean.19 A VR of 1.00 
suggests equal variance of AD and placebo. If the VR 
exceeds 1, then the variance of the AD group is larger 
than in the placebo group. If the CVR exceeds 1, then 
the increase of variance with increasing pre–post differ-
ences is stronger in the AD than in the placebo arms. 
Sensitivity analysis included meta- regression models with 
the assessment instruments, year of publication, type of 
publication (published vs unpublished), sample size and 
drop- out rates.
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Simulation analysis
To bring our results into context, we also ran simulation 
analysis with different definitions and probabilities for 
benefiters. We based these simulations on an efficacy of 2 
points mean difference between AD and placebo groups, 
as reported in a meta- analysis on the same dataset for trials 
using the HDRS-17 instrument.5 We assumed SD=8 and 
a mean difference between pre- depression and post- 
depression scores of 11 points in the AD group (based on 
rounded means of these values observed in our dataset). 
We used different cut- offs to define patients as benefiters, 
ranging from 5 to 10 points superior treatment outcome 
with the HDRS-17, and a proportion of 5%–50% in the 
AD group versus 0% in the placebo group. To simulate 
placebo groups, we sampled from a normal distribution 
with the above parameters for the placebo group (M=9, 
SD=8 and 5 000 000 samples). We used a similar sampling 
procedure for the AD group, but created benefiters by 
adding necessary HDRS responder points to an assumed 
fraction of the sample, and adding as many points to the 
rest of the sample to end up with the overall efficacy of 2 
HDRS points.
The R- code and data of this publication are available 
online (https:// osf. io/ 98kex/ files/).
reSultS
Meta-analysis
Across all ADs, the VR was almost perfectly 1.00 with a 
narrow confidence interval (VR=1.01, 95% CI=0.99 
to 1.02). This means that the variances in the AD and 
placebo groups are nearly identical (table 1). Similar 
findings were found for all classes of ADs (table 1) and 
for each individual drug (online supplementary table 2, 
https:// osf. io/ 98kex/ files/). There was no significant 
sign of heterogeneity in the meta- analyses, except for 
SSRIs. A closer inspection revealed that this resulted from 
a single outlier (see footnote in table 1).
For the CVR, results indicated that the increase of vari-
ance with increasing pre–post differences is less strong 
in AD than in placebo arms (CVR=0.82, 95% CI=0.80 to 
0.84). Comparable results were found for all classes of 
ADs and individual drugs (table 1). The heterogeneity 
was statistically significant in nearly all meta- analyses of 
the CVR.
In the sensitivity analysis, the meta- regression 
models could not detect statistically significant 
effects for year of publication, type of publica-
tion, measurement instruments, drop out rates, 
and sample size (see https:// osf. io/ 98kex/ files/). 
Simulation analysis
As shown in figure 1, most benefiter assumptions lead to 
VRs much different from those we observed in our study.
However, for liberal definitions of benefiters and low 
rates of these benefiters, the VRs can indeed be small. For 
example, if there are 10% benefiters, as defined with 6 
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Figure 1 Results from simulation analyses (hypothetical 
variance ratios) for different definitions of benefiters (x- axis) 
and different percentages of benefiters (individual lines with 
the percentages on the right side of the line). The horizontal 
thick line is the result from our meta- analysis (VR=1.01), the 
horizontal grey lines correspond with upper and lower limits 
of the CI of the meta- analysis (0.99–1.02). VR, variance ratio; 
AD, antidepressant.
HDRS points difference to average placebo response, the 
VR is within the CI of our main finding (0.99–1.02).
DISCuSSIOn
We found nearly identical treatment outcome variances 
for AD arms compared with placebo in RCTs for the 
acute treatment of major depression in a large data-
base, as indicated by VRs almost perfectly being VR=1. 
The simplest explanation for the finding of similar vari-
ances is that there are constant treatment effects and no 
treatment heterogeneity, that is, no patient- by- treatment 
interaction effects and no specific subgroups of patients 
who respond particularly well to the treatment.20 Alterna-
tively, such a subgroup of benefiters would be very small 
(≤10%) and the threshold to classify someone as bene-
fiter would be low (≤6 HDRS points difference to average 
placebo response). To put this in context, according to 
anchor- based linkage studies, at least 6 points on the 
HDRS are necessary for a global impression of ‘minimally 
improved’.21 22 Consequently, the search for meaningful 
predictors of relative treatment response (compared with 
placebo) will probably fail or will at least be very difficult 
due to the small subgroup of weak benefiters. Therefore, 
the mean effect size estimate from parallel- group RCT 
remains the best guess for predicting treatment outcome 
for an individual patient. Furthermore, the results for 
the coefficient of variance indicated that the increase of 
variance associated with increasing larger pre–post differ-
ences was stronger in the placebo than the AD groups. 
There is no immediately plausible explanation for this 
finding, given that baseline severity does not predict 
differential treatment effects.23–25
Our findings are in line with Senn,12 who argued 
that exploratory post- hoc delineation of putative bene-
fiters, such as the ‘true benefiters’ suggested by Thase 
et al,26 are simply statistical artefacts due to random 
symptom fluctuations and measurement error (see 
also Hengartner15). Our findings also replicate the 
findings for antipsychotics in the acute treatment of 
schizophrenia,16 and several treatments in a review 
of various medical interventions.17 Together, these 
studies indeed suggest that the promises of precision 
medicine may remain elusive and that the scope for 
personalised medicine might be smaller than previously 
hoped for.12 13 Given the high expectations placed in 
biomarker- based precision medicine, such findings will 
probably cause disbelief and reluctance in many advo-
cates of this enthusiastic movement. In anticipation of 
such critique, we would like to address two objections 
that are likely to be submitted in response to this paper.
First, as recently stressed by biostatistics professor Dr 
Frank Harrell, to assume that there is treatment hetero-
geneity (ie, significant patient- by- treatment interaction) 
when the average treatment effect is close to zero (which 
is the case with ADs), would imply that there must be a 
large subgroup of patients where the treatment causes 
significant harm.27 Although it has been suggested that 
ADs may worsen the long- term outcome of depression 
in some patients,28–31 there is no evidence that they may 
do harm in a large subgroup of patients in short- term 
trials. In the absence of consistent biologically- informed 
patient- specific treatment effects, our best treatment esti-
mate for ADs thus remains the average drug effect rela-
tive to placebo.27
Second, and closely related to the above argument, 
even after decades of massive research efforts there 
is no evidence of robust neurobiological and genetic 
predictors of differential treatment response in depres-
sion.6–9 32 Biostatistics professor Dr Stephen Senn once 
stated: ‘Unless patient by treatment interaction exists, 
it is pointless looking for gene by treatment interac-
tions’.33 Thus, calling for more genetic and neurobio-
logical research into differential treatment effects clearly 
conflicts with the current literature and will most likely 
fail to yield the hoped- for results.
We acknowledge the following major limitation: as 
Cortés et al17 describe in their paper, equal variances 
are no definite proof for a lack of patient- by- treatment 
interactions. They hypothetically describe a situation 
that leads to equal variances in the treatment and in the 
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control condition and with patient- by- treatment inter-
actions, but this situation is highly unlikely. Further-
more, VRs of 1 are, theoretically, also possible with a 
small fraction of ‘super- responders’ and a specific 
response for all others, as highlighted in a vivid Twitter- 
Discussion of our paper (https:// twitter. com/ Martin_ 
Ploederl/ status/ 1188006207497363457). It can indeed 
be debated what assumption is more plausible: a 
constant treatment effect, a hypothetical fraction of 
super- responders or other highly specific premises. 
However, a small fraction of super- responders would 
obviously lead to non- normal distributions with notable 
peaks at very low levels of depression scores. This was 
not observed so far, to our knowledge,26 but could be 
further investigated with patient level data. Moreover, 
VRs would increase for a wide range of scenarios with 
varying fractions of benefiters and varying definitions 
of ‘benefiters’.
Another potential problem may be, as one reviewer 
pointed out, that the VRs did not vary much across trials, 
as indicated by the Q statistics, and also by the low I2 
statistics. However, the main results remained the same 
for different estimators of heterogeneity, unweighted 
results or with the Knapp and Hartung adjustment (see 
online supplementary table 3). Furthermore, by manu-
ally increasing the value of the heterogeneity, results 
remained comparable. Presumably, the low between- trial 
heterogeneity was caused by insufficient randomisation 
of trials, or due to narrow and selective inclusion criteria 
for trial participants.34
In conclusion, the results of our meta- analysis suggest 
that there is no or at best a very small patient- by- treatment 
interaction. The lack of increased outcome variance in 
the AD versus placebo groups in parallel- group RCT indi-
cates that no specific subgroup of patients may respond 
particularly well to ADs. Thus, with the ADs currently 
available, the scope for personalised AD treatments is 
probably limited and it is unlikely that precision psychi-
atry will succeed in finding clinical or biological predic-
tors of differential treatment response that would account 
for a therapeutic effect that goes beyond a minimal clin-
ical improvement.
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